Prioritizing vaccine introduction to China’s National Immunization Program: a multi-criteria decision analysis by Jianming Guo, Bin Zheng, Tingting Chen, Shuyan Guo, Maobai Liu, Siping Dong

Get full text

First-line treatment with zolbetuximab plus CAPOX for ClDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a cost-effectiveness analysis by Jianying Lei, Jiahao Zhang, Caicong You, Wu Fu, Maobai Liu, Na Li

Get full text

Cost-effectiveness analysis of anlotinib plus chemotherapy with or without benmelstobart versus chemotherapy alone for extensive-stage small-cell lung cancer in China by Caicong You, Caicong You, Jiahao Zhang, Jiahao Zhang, Jianying Lei, Jianying Lei, Wu Fu, Wu Fu, Bin Zheng, Bin Zheng, Maobai Liu, Maobai Liu, Na Li, Na Li

Get full text

Cost-effectiveness of nivolumab combined with chemotherapy as a first-line therapy for patients with unresectable or metastatic urothelial carcinoma by Jingwen Lin, Xiaobing Song, Wu Fu, Caicong You, Na Li, Maobai Liu, Hongfu Cai

Get full text

Cost-effectiveness analysis of durvalumab with chemotherapy and maintenance durvalumab with or without olaparib for advanced endometrial cancer by Jiahao Zhang, Jianying Lei, Caicong You, Wu Fu, Bin Zheng, Hongfu Cai, Maobai Liu, Na Li

Get full text

Expert consensus on the off-label use in China of drugs for rare hematologic diseases (2024 edition) by Boxin Zhao, Boxin Zhao, Xuan Zhou, Ping Zheng, Ping Zheng, Bo Zhang, Bo Zhang, Xiaoqin Feng, Jie Chen, Lisheng Cai, Yilu Chen, Liya He, Jianfen Su, Shuqin Cheng, Yingtong Zeng, Guowei Li, Bo Ji, Jianlong Wu, Weiyi Feng, Maobai Liu, Yiran Jin, Taotao Liu, Xiaolan Mo, Junyan Wu, Hui Wu, Hongliang Zhang, Zhichang Zheng, Zhihua Zheng, Jing Sun, Yilei Li, Yilei Li, Guangdong Pharmaceutical Association, Hematology Group of Rare Disease Expert Committee of Guangdong Pharmaceutical Association

Get full text